Synergistic Cancer Treatment System with AI, IoT, Blockchain, and Nanoparticle Delivery

Publication ID: 24-11857601_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Cancer Treatment System with AI, IoT, Blockchain, and Nanoparticle Delivery,” Published Technical Disclosure No. 24-11857601_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857601_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,601.

Summary of the Inventive Concept

A novel cancer treatment system integrating a fusion protein dimer with IL-2 and CD80 proteins, an anticancer agent, and advanced technologies like AI, IoT, blockchain, and nanoparticle delivery to enhance treatment efficacy, patient monitoring, and data management.

Background and Problem Solved

The original patent disclosed a pharmaceutical composition for cancer treatment comprising a fusion protein dimer and an anticancer agent. However, this invention has limitations in terms of treatment monitoring, data management, and personalized treatment strategies. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and effective system.

Detailed Description of the Inventive Concept

The system comprises a fusion protein dimer including IL-2 protein and CD80 protein, an anticancer agent, and a blockchain-based data storage module for tracking patient treatment history and outcomes. Additionally, the system incorporates an AI-powered algorithm for predicting treatment efficacy based on patient-specific biomarkers and a nanoparticle-based delivery system for targeted and controlled release of the fusion protein and anticancer agent. The system may also include an IoT-based wearable device for monitoring patient vital signs and adjusting treatment dosages in real-time.

Novelty and Inventive Step

The new claims introduce novel and non-obvious synergies between the fusion protein dimer, anticancer agent, and advanced technologies like AI, IoT, blockchain, and nanoparticle delivery. The inventive step lies in the integration of these distinct technologies to create a more effective and personalized cancer treatment system.

Alternative Embodiments and Variations

Alternative embodiments may include different AI algorithms, IoT devices, or nanoparticle delivery systems. Variations may also include integrating other advanced technologies, such as gene editing or immunotherapy, to further enhance treatment outcomes.

Potential Commercial Applications and Market

The synergistic cancer treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and cancer treatment. The system's ability to enhance treatment efficacy, monitor patient outcomes, and manage data securely makes it an attractive solution for healthcare providers and patients.

CPC Classifications

SectionClassGroup
A A61 A61K38/2013
A A61 A61K31/337
A A61 A61K31/444
A A61 A61K31/4439
A A61 A61K31/47
A A61 A61K31/4709
A A61 A61K31/502
A A61 A61K31/506
A A61 A61K31/5025
A A61 A61K31/519
A A61 A61K31/708
A A61 A61K33/243
A A61 A61K38/1774
A A61 A61K39/3955
A A61 A61K45/06
A A61 A61P35/00

Original Patent Information

Patent NumberUS 11,857,601
TitlePharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
Assignee(s)GI Innovation, Inc.